Teva Denied On LAI Risperidone But Expected To Bounce Back ‘Quickly’
Israeli Firm ‘Reviewing Its Next Steps’ And Will ‘Work Closely’ With FDA
Development partners Teva and MedinCell are not licking their wounds after being denied USFDA approval for their proposed 505(b)(2) hybrid risperidone long-acting injectable product.
